Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-11-23

FDA Approved: INREBIC — Supplemental Application (Celgene Corporation)

View source ↗

Summary

FDA approved a supplemental application for INREBIC (fedratinib hydrochloride) from Celgene Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INREBIC (fedratinib hydrochloride)

Snippet

SUPPL AP for INREBIC (FEDRATINIB HYDROCHLORIDE)